Tvardi Therapeutics Reports Q3 2026 Net Loss of $6.1 Million
Tvardi Therapeutics reported a Q3 2026 net loss of $6.1M, up from $5.5M a year earlier. R&D expenses rose to $4.5M, while G&A expenses fell to $1.9M. The company had $22.3M in cash and expects funds to last into Q3 2027. Tvardi is preparing to advance TTI-109 into clinical trials for ulcerative colitis and expects Phase 1b/2 REVERT LIVER CANCER study results in early Q1 2027.
How this was made

The 30-second read
Why it matters
The earnings release highlights a widening loss but also progress in its pipeline, which may influence short‑term trading sentiment.
Market read
Micro‑cap biotech earnings with modest cash runway and pipeline updates; likely short‑term downside pressure.
What to watch
Potential non‑dilutive funding sources or partnership deals not disclosed in the filing.
Background
Tvardi Therapeutics is a clinical‑stage biotech focusing on STAT3 inhibition for inflammatory diseases and liver cancer.
Ticker impact
Tvardi Therapeutics disclosed its Q3 2026 earnings, reporting a net loss of $6.1 million and cash balance of $22.3 million.
likely downward pressure as investors digest the loss and limited cash runway
Earnings miss and cash constraints typically weigh on micro‑cap biotech shares, while pipeline progress may limit the decline.
Market effects
Biotech sector may see modest pullback as micro‑cap earnings miss, but pipeline news could buoy peers focused on ulcerative colitis and liver cancer.
US biotech investors may adjust exposure to early‑stage companies with limited cash.
Limited to investors tracking small‑cap biotech pipelines.
Counterpoint
If the upcoming TTI‑109 trial data exceeds expectations, the stock could rebound sharply despite the loss.
Key entities
- companyTvardi Therapeutics
Clinical‑stage biotech reporting Q3 2026 results.
